Related Experiment Video
Updated: Sep 10, 2025
08:58
Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
Published on: March 11, 2017
16.1K
Glucagon Receptor Deficiency Causes Early-Onset Hepatic Steatosis
Tessa M Cacciottolo1, Katherine Lawler1, Kevin M Méndez-Acevedo1
1University of Cambridge Metabolic Research Laboratories and National Institute for Health Research Cambridge Biomedical Research Centre, Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, U.K.
Diabetes
|August 25, 2025
Summary
Genetic variants in the glucagon receptor (GCGR) gene were linked to hepatic steatosis and cirrhosis in a consanguineous family. These findings suggest potential therapeutic strategies involving GCGR modulation.
Area of Science:
- Genetics
- Metabolic Disorders
- Hepatology
Background:
- Hepatic steatosis and cirrhosis can occur in individuals with normal weight.
- Consanguineous families present unique genetic research opportunities.
Purpose of the Study:
- To identify the genetic cause of hepatic steatosis and cirrhosis in a consanguineous family.
- To understand the functional impact of identified genetic variants on glucagon receptor (GCGR) activity and lipid metabolism.
Main Methods:
- Whole-exome sequencing was employed to identify genetic variants.
- Segregation analysis was performed to confirm cosegregation of variants with the phenotype.
- Cellular assays were utilized to assess the functional consequences of GCGR mutations.
Main Results:
- Two rare homozygous variants in the glucagon receptor (GCGR) gene were identified.
- These GCGR variants cosegregated with hepatic steatosis and cirrhosis within the family.
- In vitro studies demonstrated that the GCGR mutations lead to a loss of function and increased lipid accumulation in cells.
Conclusions:
- Loss-of-function mutations in the glucagon receptor (GCGR) gene can cause hepatic steatosis and cirrhosis.
- GCGR antagonists may pose risks for developing fatty liver disease.
- GCGR agonists could offer therapeutic benefits for metabolic liver conditions.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
416
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
416
01:15Hypoglycemia and Glucagon
334
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
334
01:27Glucose Transporters
24.1K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
24.1K
01:28Insulin: The Receptor and Signaling Pathways
1.5K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
1.5K
01:20Inborn Errors of Metabolism
241
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
241
01:16Hormones Regulating Blood Glucose
4.0K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
4.0K